• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Averion Restructures as Revenues Dip

Averion Restructures as Revenues Dip

August 21, 2009
CenterWatch Staff

Southborough, Mass.-based contract research organization (CRO) Averion is restructuring its senior management team in an effort to grow its services and improve its bottom line.

The CRO, which specializes in oncology, cardiovascular disease and medical devices, appointed Peter Gonze president and James McGuire chairman of the board of directors. Gonze, who joined the company a year ago as executive vice president of global business development, will be responsible for global operations and business development. McGuire was formerly president of private equity investor NJK Holding Corporation, an affiliate of Cumulus Investors, Averion’s second largest stakeholder.

Former CEO Markus Weissbach, M.D., Ph.D., is now executive chairman following the July resignation of Philip Lavin, Ph.D. Lavin was given the title of founder and vice chairman of the board, and Weissbach, who has been CEO since Averion’s 2007 acquisition of Swiss-based CRO Hesperion, will focus on strategy and planning.

Averion also reached an agreement with senior debt holders to modify the terms of certain interest payments that are due in order to preserve working capital for the growth of the business and to strengthen the long-term growth prospects of the company.

The CRO reported last week a drop in net service revenues for the second quarter 2009 due to a lower level of contract signings that would have been recognizable in Q2. Revenues decreased $2.8 million to $15.9 million, compared with $18.7 million for the same period last year. Year-to-date net service revenues also decreased, from $34.4 million in 2008 to $31.6 million in 2009.

Averion’s net loss for the quarter increased to $1.2 million, up from $0.6 million last year.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing